slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
The Massachusetts BioReady TM Community Campaign PowerPoint Presentation
Download Presentation
The Massachusetts BioReady TM Community Campaign

play fullscreen
1 / 34
Download Presentation

The Massachusetts BioReady TM Community Campaign - PowerPoint PPT Presentation

Download Presentation

The Massachusetts BioReady TM Community Campaign

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. March 22, 2012 The Massachusetts BioReadyTM Community Campaign Presented to South Shore/Canal Regional Economic Development District

  2. Advocacy for industry on Beacon Hill and Capitol Hill Savings from 20-80% on everything from lab gases, lab equipment, supplies, office equipment, energy and much more. 110+ member meetings, 4,000 attendees MassBioEd Courses, MassBio Committee Meetings About MassBio To foster a positive environment that enables each biotechnology company to achieve its full potential

  3. About Biotechnology The use of biological processes to solve problems or make useful products. Biotechnology is a collection of technologies that capitalize on the attributes of cells, such as their manufacturing capabilities, and put biological molecules, such as DNA and proteins, to work for us. Pharmaceuticals are chemical-based medicines Biologic-based Medicines Biologic-based Medical Devices Biological Research Tools Biofuels, AgBio,Bio Industrials

  4. Massachusetts Biotech Timeline

  5. The Difficult Path to Bring a Drug to Market • For every 5,000 investigational drugs that begin down the path, • only 1 is successfully commercialized. • Average research and development cost of is $1 billion.

  6. Massachusetts BioPharma Employment Growth 2011 49,825 53% Growth Since 2002 2002 32,571 Source: U.S. Census, County Business Patterns and MassBio formula and analysis. *2010 figure is a final estimate based on review of Massachusetts ES-202 data for 2010. 2011 figure is a preliminary estimate.

  7. Biotechnology R&D Employment According to the Bureau of Labor Statistics’ Quarterly Census of Employment & Wage (QCEW) data, Massachusetts leads the nation in biotechnology research & development employment. Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)

  8. WA PA NC NY NJ MO MI MD MA CA Biotech R&D Employment, 2007-2010 Massachusetts grew biotechnology research employment between 2007-2010. Massachusetts was outpaced only by California. Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)

  9. Biotechnology Research Concentration Massachusetts holds a dominant position in terms of industry concentration in “Biotechnology Research and Development” – almost twice the concentration of jobs as the next closest state. The Massachusetts concentration did, however, decline slightly from 2009. What is a Location Quotient? Location Quotients measure the concentration and strength of an industry in a region versus the nation as a whole. Location Quotients of more that 1.0 mean that the industry enjoys a greater concentration in a region versus the nation as a whole. Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)

  10. Biotech R&D Employment: U.S. Counties Among leading U.S. counties in biotech R&D employment, Middlesex County in Massachusetts continues to stand out. Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)

  11. BioPharma Manufacturing Employment 2010 Only Massachusetts, Maryland, and North Carolina have grown biopharma manufacturing jobs since 2006. 9,514 Massachusetts was one of only 3 states to grow biopharma manufacturing jobs between 2006 and 2010. 2006 7,944 Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)

  12. Drug Development Pipeline August 2011 Massachusetts- headquartered companies* account for about 10% of the U.S. drug development pipeline and 5% of the global pipeline. Candidate medicines of Massachusetts-headquartered* companies, by clinical trials stage Massachusetts-headquartered companies’ share of U.S. and Global drug development pipeline * There are many drugs in development in Massachusetts by companies with headquarters located outside of Massachusetts. These candidate drugs are not included in any Massachusetts pipeline estimates found in this report. Source: MedTrack Online, Life Sciences Analytics, Inc.

  13. Massachusetts Drug Pipeline Movement: May 2010-April 2011 Between May 2010 and April 2011, 217 candidate drugs advanced in the development pipeline – from entering into pre-clinical trials through advancing to approval by the FDA. Source: MedTrack Online, Life Sciences Analytics, Inc.

  14. Why Massachusetts? 500+ 430+ Biopharma Biotech Companies Companies Top 5 Top 5 122 122 NIH funded NIH funded Colleges & Colleges & Research Research Universities Universities Hospitals Hospitals 1 1 st st 1 1 st st in in in in Venture Capital Venture Capital Education Education & SBIR funds & federal research Level of Level of per worker funds per worker Workforce (US) workforce Supportive Local, State Government Life Sciences Initiative Biotech Caucus

  15. Top 5 NIH Funded Hospitals in U.S., FY 2011 1. Massachusetts General Hospital ($324,620,848) 2. Brigham and Women's Hospital ($288,436,449) 3. Beth Israel Deaconess Medical Center ($131,304,171) 4. Dana-Farber Cancer Institute ($130,136,550) 5. Children's Hospital Boston ($118,512,044) Source: National Institute of Health; 2009

  16. Top 5 Massachusetts NIH-funded Universities, FY 2010* • Harvard University $393 M • University of Massachusetts $196M • Boston University $163 M • Massachusetts Institute of Technology $158 M • Tufts University $136 M *includes ARRA funds.

  17. National Institutes of Health Funding, 2010 On a NIH-funding per capita basis, Massachusetts far exceeded other leading NIH-recipient states. Sources: National Institutes of Health, U.S. Census Bureau.

  18. Venture Capital Investment $1.071 billion invested in MA biotechs in 2011 is an historic high. $8.054 billion since 2002 Source Data: 2011 PricewaterhouseCoopers, National Venture Capital Association, MoneyTreeTM Report, Historical Trend Data, and MassBio analysis.

  19. MA Share of the Biotech VC Dollar MA biotechs received 22.6% of all VC biotech financing, just below the 2010 all-time high. Source: 2011 PricewaterhouseCoopers, National Venture Capital Association, MoneyTreeTM Report, Historical Trend Data, MassBio analysis.

  20. BioPharma Industry Impact in MA The estimated average salary in the biopharma industry is 77% higher than the estimated state average salary of $53,834. $4,615,364,513 in payroll (2010) $95,628 in average salary (2010) Source: U.S. Census, County Business Patterns, MassBio estimate using 2009 base data, MassExport Center.

  21. Leading BioPharma Employers (MA), 2011 1. Genzyme (Sanofi) 4,356 2. Pfizer 2,600 3. Biogen Idec 2,300 4. Novartis 2,100 5. Thermo Fisher Scientific 1,700 6. Shire 1,500 7. Vertex 1,310 8. EMD Millipore 1,237 9. Parexel International 1,200 10. Millenium: Takeda Oncology 1,050 11. Charles River Laboratories 970 12. AstraZeneca 900 13. EMD Serono 850 14. Hologic 800 15. Abbott Laboratories 750 16. Sunovion Pharmaceuticals (DSP) 690 17. Nova Biomedical 631 18. Cubist 626 19. Lantheus 550 19. Merck 330 20. Bristol-Myers Squibb 320 MA has benefited from the pharma industry’s embrace of biotechnology. Sources: MassBio, membership reports, survey, Boston Business Journal Book of Lists, 2011.

  22. The $1 Billion Massachusetts Life Sciences Initiative Over time, the industry demonstrated its value, commitment to the region, and promise for the future . . . and state government responded. $250 millionTax Incentive Program $500 million Capital Fund • 10 years • $1 billion • Investment $250m Investment Fund (subject to appropriation)

  23. Top 20 job listing categories on in 2011 6,223 total jobs listed in 2011

  24. Job Listings by desired education level, 2011 HS/Vocational/Certification, 283 Associate’s Degree, 200 Master’s Degree, 717 Bachelors Degree 3,416 PhD, 797 Unspecified 810 6,223 jobs listed in 2011

  25. Projected Job Growth by Industry and Selected Occupations “Middle skill” occupations Source: Massachusetts Industry-Occupation Employment Matrix, 2008-2018, MA DLWD.

  26. Biotech/Pharma Buildings Abbott Bioresearch, Worcester, MA EMD Serono, Rockland, MA AstraZeneca R&D Boston, Waltham, MA

  27. Biotech/Pharma Buildings Biotechnology Laboratory Facilities Biotechnology Manufacturing Facilities

  28. Laboratory Safety BioSafety Level 2 BioSafety Level 1 BioSafety Level 3 Suitable for work involving well characterized agents not known to cause disease in healthy adult humans and of minimal potential hazard to laboratory personnel and the environment. Suitable for work with infectious agents which may cause serious or potentially lethal disease as a result of exposure by the inhalation route. Suitable for work involving agents of moderate potential hazard to personnel and the environment. Source: Centers for Disease Control

  29. Manufacturing Safety Good Manufacturing Practice regulations (GMPs) are used by pharmaceutical and medical device manufacturers as they produce and test products that people use. In the United States, the U.S. Food and Drug Administration (FDA) has issued these regulations as the minimum requirements. • Human pharmaceutical products and veterinary products (21 CFR 210-211) • Biologically derived products (21 CFR 600 and 21 CFR 620) • Medical devices (21 CFR 820) The manufacturing or "production" area is where the drug products are actually made with the active pharmaceutical ingredients and other materials such as high-purity water or sugars and other binding/lubricating agents. Depending on the final product, the manufacturing process can be very simple or extremely complicated. Labeling in Laboratory Laboratory Instrumentation Quality assurance Quality Control Facilities Control Room Validation Source: Learning Plus, Inc.

  30. Snapshot of Lab & Plant Physical Requirements

  31. BioReadyTM Ratings Criteria Bronze - A municipality at this level features municipal water and sewer in commercial and industrial areas, zoning allowing for biotech laboratory and manufacturing uses by special permit, and has identified a local point of contact in to assist biotech projects. Silver - A municipality meets all Bronze criteria AND allows biotech uses by right, convene Site Plan Review meetings to expedite development projects, and has identified sites for biotech uses in municipal plans or has land sites and/or buildings included in BioSites inventory at, or is aGrowth District, or has identified Priority Development Sites per Chapter 43D. Gold - A municipality meets Silver criteria plus has sites or buildings pre-permitted for biotechnology use, OR has existing buildings in which biotech laboratory or manufacturing activities are taking place. Platinum - A municipality meets Gold criteria plus has adopted the National Institutes of Health guidelines on rDNA activity as part of its Board of Health regulations, has a building or buildings that are already permitted for biotech uses and which have 20,000+ square feet available space for biotech uses OR has a shovel-ready pre-permitted land site with completed MEPA review and municipal water and sewer capacity to meet additional demand.

  32. BioReadyTM Communities Map

  33. Community Guide for Biotechnology Available for download at MassBio BioReady web pages.

  34. Next Steps • See BioReadyTM guidance at • Download Biotechnology Community Guide • Take a look at the BioReadyTM survey • Call with any questions: Pete Abair, 617-674-5130 • We travel! Happy to visit your town to discuss. • When you are ready, submit a BioReadyTM Survey for your municipality • Get you BioReadyTM buildings and sites onto’s real estate web pages